For the first time in Europe hundreds of rare disease (RD) experts team up to actively share and jointly analyse existing patient’s data. Solve-RD is a Horizon 2020-supported EU flagship project bringing together >300 clinicians, scientists, and patient representatives of 51 sites from 15 countries. Solve-RD is built upon a core group of four European Reference Networks (ERNs; ERN-ITHACA, ERN-RND, ERN-Euro NMD, ERN-GENTURIS) which annually see more than 270,000 RD patients with respective pathologies. The main ambition is to solve unsolved rare diseases for which a molecular cause is not yet known. This is achieved through an innovative clinical research environment that introduces novel ways to organise expertise and data. Two major approaches are being pursued (i) massive data re-analysis of >19,000 unsolved rare disease patients and (ii) novel combined -omics approaches. The minimum requirement to be eligible for the analysis activities is an inconclusive exome that can be shared with controlled access. The first preliminary data re-analysis has already diagnosed 255 cases form 8393 exomes/genome datasets. This unprecedented degree of collaboration focused on sharing of data and expertise shall identify many new disease genes and enable diagnosis of many so far undiagnosed patients from all over Europe.

Solve-RD: systematic pan-European data sharing and collaborative analysis to solve rare diseases

Ferlini A.
Membro del Collaboration Group
;
Selvatici R.
Membro del Collaboration Group
;
Rossi R.
Membro del Collaboration Group
;
Neri M.
Membro del Collaboration Group
;
2021

Abstract

For the first time in Europe hundreds of rare disease (RD) experts team up to actively share and jointly analyse existing patient’s data. Solve-RD is a Horizon 2020-supported EU flagship project bringing together >300 clinicians, scientists, and patient representatives of 51 sites from 15 countries. Solve-RD is built upon a core group of four European Reference Networks (ERNs; ERN-ITHACA, ERN-RND, ERN-Euro NMD, ERN-GENTURIS) which annually see more than 270,000 RD patients with respective pathologies. The main ambition is to solve unsolved rare diseases for which a molecular cause is not yet known. This is achieved through an innovative clinical research environment that introduces novel ways to organise expertise and data. Two major approaches are being pursued (i) massive data re-analysis of >19,000 unsolved rare disease patients and (ii) novel combined -omics approaches. The minimum requirement to be eligible for the analysis activities is an inconclusive exome that can be shared with controlled access. The first preliminary data re-analysis has already diagnosed 255 cases form 8393 exomes/genome datasets. This unprecedented degree of collaboration focused on sharing of data and expertise shall identify many new disease genes and enable diagnosis of many so far undiagnosed patients from all over Europe.
2021
Zurek, B.; Ellwanger, K.; Vissers, L. E. L. M.; Schule, R.; Synofzik, M.; Topf, A.; de Voer, R. M.; Laurie, S.; Matalonga, L.; Gilissen, C.; Ossowski, S.; 't Hoen, P. A. C.; Vitobello, A.; Schulze-Hentrich, J. M.; Riess, O.; Brunner, H. G.; Brookes, A. J.; Rath, A.; Bonne, G.; Gumus, G.; Verloes, A.; Hoogerbrugge, N.; Evangelista, T.; Harmuth, T.; Swertz, M.; Spalding, D.; Hoischen, A.; Beltran, S.; Graessner, H.; Haack, T. B.; Zurek, B.; Ellwanger, K.; Demidov, G.; Sturm, M.; Kessler, C.; Wayand, M.; Wilke, C.; Traschutz, A.; Schols, L.; Hengel, H.; Heutink, P.; Brunner, H.; Scheffer, H.; Steyaert, W.; Sablauskas, K.; de Voer, R. M.; Kamsteeg, E. -J.; van de Warrenburg, B.; van Os, N.; te Paske, I.; Janssen, E.; de Boer, E.; Steehouwer, M.; Yaldiz, B.; Kleefstra, T.; Veal, C.; Gibson, S.; Wadsley, M.; Mehtarizadeh, M.; Riaz, U.; Warren, G.; Dizjikan, F. Y.; Shorter, T.; Straub, V.; Bettolo, C. M.; Specht, S.; Clayton-Smith, J.; Banka, S.; Alexander, E.; Jackson, A.; Faivre, L.; Thauvin, C.; Vitobello, A.; Denomme-Pichon, A. -S.; Duffourd, Y.; Tisserant, E.; Bruel, A. -L.; Peyron, C.; Pelissier, A.; Beltran, S.; Gut, I. G.; Laurie, S.; Piscia, D.; Matalonga, L.; Papakonstantinou, A.; Bullich, G.; Corvo, A.; Garcia, C.; Fernandez-Callejo, M.; Hernandez, C.; Pico, D.; Paramonov, I.; Lochmuller, H.; Gumus, G.; Bros-Facer, V.; Hanauer, M.; Olry, A.; Lagorce, D.; Havrylenko, S.; Izem, K.; Rigour, F.; Stevanin, G.; Durr, A.; Davoine, C. -S.; Guillot-Noel, L.; Heinzmann, A.; Coarelli, G.; Allamand, V.; Nelson, I.; Yaou, R. B.; Metay, C.; Eymard, B.; Cohen, E.; Atalaia, A.; Stojkovic, T.; Macek, M.; Turnovec, M.; Thomasova, D.; Kremlikova, R. P.; Frankova, V.; Havlovicova, M.; Kremlik, V.; Parkinson, H.; Keane, T.; Senf, A.; Robinson, P.; Danis, D.; Robert, G.; Costa, A.; Patch, C.; Hanna, M.; Houlden, H.; Reilly, M.; Vandrovcova, J.; Muntoni, F.; Zaharieva, I.; Sarkozy, A.; Timmerman, V.; Baets, J.; Van de Vondel, L.; Beijer, D.; de Jonghe, P.; Nigro, V.; Banfi, S.; Torella, A.; Musacchia, F.; Piluso, G.; Ferlini, A.; Selvatici, R.; Rossi, R.; Neri, M.; Aretz, S.; Spier, I.; Sommer, A. K.; Peters, S.; Oliveira, C.; Pelaez, J. G.; Matos, A. R.; Jose, C. S.; Ferreira, M.; Gullo, I.; Fernandes, S.; Garrido, L.; Ferreira, P.; Carneiro, F.; Swertz, M. A.; Johansson, L.; van der Velde, J. K.; van der Vries, G.; Neerincx, P. B.; Roelofs-Prins, D.; Kohler, S.; Metcalfe, A.; Verloes, A.; Drunat, S.; Rooryck, C.; Trimouille, A.; Castello, R.; Morleo, M.; Pinelli, M.; Varavallo, A.; De la Paz, M. P.; Sanchez, E. B.; Martin, E. L.; Delgado, B. M.; de la Rosa, F. J. A. G.; Ciolfi, A.; Dallapiccola, B.; Pizzi, S.; Radio, F. C.; Tartaglia, M.; Renieri, A.; Benetti, E.; Balicza, P.; Molnar, M. J.; Maver, A.; Peterlin, B.; Munchau, A.; Lohmann, K.; Herzog, R.; Pauly, M.; Macaya, A.; Marce-Grau, A.; Osorio, A. N.; de Benito, D. N.; Lochmuller, H.; Thompson, R.; Polavarapu, K.; Beeson, D.; Cossins, J.; Cruz, P. M. R.; Hackman, P.; Johari, M.; Savarese, M.; Udd, B.; Horvath, R.; Capella, G.; Valle, L.; Holinski-Feder, E.; Laner, A.; Steinke-Lange, V.; Schrock, E.; Rump, A.
File in questo prodotto:
File Dimensione Formato  
European Journal of Human Genetics 2021_1325–1331.pdf

accesso aperto

Descrizione: Full text editoriale
Tipologia: Full text (versione editoriale)
Licenza: Creative commons
Dimensione 2.4 MB
Formato Adobe PDF
2.4 MB Adobe PDF Visualizza/Apri

I documenti in SFERA sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11392/2470732
Citazioni
  • ???jsp.display-item.citation.pmc??? 35
  • Scopus 44
  • ???jsp.display-item.citation.isi??? 43
social impact